Back to home
CLINICAL SIGNALApril 13, 2026·6 min read
GLP-1 Agonists Enter Neuroprotection Era: Six Parkinson's Trials and Counting
A systematic review finds six published trials of GLP-1 therapies in Parkinson's disease, with lixisenatide's LIXIPARK trial showing superiority over placebo on motor endpoints. The data fuels a growing hypothesis that incretin-based drugs may slow neurodegeneration — not just metabolic disease.
The full analysis is published in the weekly biotech.today newsletter — subscribe for free to get the next issue in your inbox.